Methods of treating tardive dyskinesia and other movement disorders
The present invention describes a novel treatment for movement disorders, including tardive dyskinesia, tic disorders, Tourette's syndrome, and blepharospasm, and other focal dystonias. The treatment of the present invention utilizes agents that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists. Preferably these two activities are characteristic of a single agent, for example acamprosate. Alternatively, separate agents having these activities can be combined and administered together. The invention also provides a third agent that acts as a non-competitive NMDA-receptor blocking agent or ion channel blocker that augments the effect of the primary treatment. A particularly preferred ion channel blocking agent is magnesium. Alternatively, magnesium can be administered alone for prevention and treatment of movement disorders.
1. A method for treating hyperkinesia comprising administering an effective dose of acamprosate in an amount of about 1 g to about 2.6 g per day.
2. The method of claim 1 , wherein said step of administering comprises oral administration.
3. A method of treating a hyperkinetic movement disorder comprising the step of administering an effective dose of acamprosate in an amount of about 1 g to about 2.6 g per day.
4. The method of claim 3 , wherein the hyperkinetic movement disorder is tardive dyskinesia or comprises involuntary movements similar to those seen in said tardive dyskinesia.
5. The method of claim 3 , wherein said movement disorder is the peak-dose dyskinesia in a patient with Parkinson's disease.
6. The method of claim 3 , wherein said movement disorder is associated with Huntington's disease.
7. The method of claim 3 , wherein said movement disorder is related to a deficiency in GABA in the basal ganglia.
8. The method of claim 3 , wherein said movement disorder is related to NMDA-based excitotoxicity.
9. The method of claim 3 comprising the further steps of:
selecting an agent that is a noncompetitive antagonist at NMDA receptors; and
administering said agent in conjunction with said acamprosate.
10. The method of claim 9 , wherein said agent is memantine or a derivative thereof.
11. The method of claim 1 , wherein the hyperkinesia comprises tardive dyskinesia.
12. A method of treating tardive dyskinesia, comprising providing a patient suffering from tardive dyskinesia with an effective dose of acamprosate in an amount of about 1 g to about 2.6 g per day.